Myristoyllysophosphatidylcholine
Myristoyllysophosphatidylcholine is a NLRP3 inflammasome inhibitor with multiple activities including anti-inflammatory and antioxidant effects. Myristoyllysophosphatidylcholine inhibits LPS-induced NLRP3 inflammasome activation, reduces pro-inflammatory cytokine secretion, decreases ROS and MDA levels, alleviates lung tissue and cell damage, and mediates apoptosis. Myristoyllysophosphatidylcholine serves as a myristate donor for myristoylation of the Glucose-6-Phosphate Isomerase (GPI) anchor in Trypanosoma brucei and undergoes hydrolysis. Myristoyllysophosphatidylcholine acts as a biomarker for the severity of community-acquired pneumonia. Myristoyllysophosphatidylcholine can be used in research related to diseases such as community-acquired pneumonia and acute lung injury.
For research use only. We do not sell to patients.
- CAS No.: 13699-45-1
- Formula: C22H46NO7P
- Molecular Weight:467.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
NLRP3 |
IL-1β |
IL-6 |
Caspase-1 |
TNF-α |
In Vitro
Myristoyllysophosphatidylcholine (LPC 14:0) (10-40 μM; 1 h pretreatment, 12 h LPS exposure) shows no toxicity to RAW 264.7 cells at concentrations up to 20 μM, while higher concentrations combined with LPS reduce cell viability[1].
Myristoyllysophosphatidylcholine (20 μM; 1 h pretreatment, 12 h LPS exposure) significantly reduces LPS-induced apoptosis and ROS production in RAW 264.7 cells; it significantly attenuates the depletion of SOD and GSH; and it significantly inhibits the secretion of IL-1β, IL-6, and TNF-α[1].
Myristoyllysophosphatidylcholine (10-20 μM; 1 h pretreatment, 12 h LPS exposure) significantly inhibits LPS-induced activation of the NLRP3 inflammasome in RAW 264.7 cells, including reducing the expression of NLRP3, TXNIP, Caspase-1 and IL-1β[1].
Myristoyllysophosphatidylcholine (M-LPC) radiolabeled probe [3H]myristoyllysophosphatidylcholine (78 nM; 0-40 min) labels free GPI lipids in cultured Trypanosoma brucei MITat 1.2 variant 221 at an identical rate to [3H]myristate, undergoes rapid hydrolysis to extracellular free myristic acid, and labels phosphatidylcholine in serum-free medium[2].
Myristoyllysophosphatidylcholine (2.5 µM) inhibits VSG myristoylation mediated by 360 nM [3H]myristic acid by 30% in cultured Trypanosoma brucei MITat 1.2 strain 221 variant[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 cells
-
Concentration:10, 20, 30, 40 μM
-
Incubation Time:1 h (pretreatment); 12 h (LPS exposure)
-
Result:Exhibited no toxicity to RAW 264.7 cells at concentrations of 10, 20, 30, and 40 μM when administered alone.
Significantly reduced cell viability at concentrations of 30 and 40 μM when combined with 1 μg/mL LPS, while 10 and 20 μM showed no significant difference from the control.
-
Cell Line:RAW 264.7 cells
-
Concentration:20 μM
-
Incubation Time:1 h (pretreatment); 12 h (LPS exposure)
-
Result:Reduced the LPS-induced apoptosis ratio of RAW 264.7 cells.
-
Cell Line:RAW 264.7 cells
-
Concentration:20 μM
-
Incubation Time:1 h (pretreatment); 12 h (LPS exposure)
-
Result:Reduced the secretion of IL-1β, IL-6, and TNF-α.
-
Cell Line:RAW 264.7 cells
-
Concentration:10, 20 μM
-
Incubation Time:1 h (pretreatment); 12 h (LPS exposure)
-
Result:Reduced LPS-induced activation of the NLRP3 inflammasome, including reduced expression of NLRP3, TXNIP, Caspase-1, and IL-1β, in RAW 264.7 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (8-week-old male, SPF-grade, LPS-induced ALI)[1]
-
Dosage:10 mg/kg
-
Administration:s.c.; 2 doses (2 hours before LPS instillation, 10 hours after LPS instillation)
-
Result:Cut lung injury score, lung W/D ratio, BALF total protein, BALF total cell count, lung MPO activity, BALF IL-1β and TNF-α, as well as lung MDA content.
Elevated lung GSH concentration and SOD specific activity.
Suppressed LPS-triggered upregulation of NLRP3, TXNIP, Caspase-1 and IL-1β protein in lung tissue.
Chemical Information
-
CAS No. 13699-45-1
-
Molecular Weight 467.58
-
Formula C22H46NO7P
-
SMILES
O=C(OCC(O)COP(=O)([O-])OCC[N+](C)(C)C)CCCCCCCCCCCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
[1]. Nan W, et al. Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia. Redox biology. 2022 Dec;58:102556. [Content Brief]
[2]. Werbovetz KA, et al. Lipid metabolism in Trypanosoma brucei: utilization of myristate and myristoyllysophosphatidylcholine for myristoylation of glycosyl phosphatidylinositols. The Biochemical journal. 1996 Sep 01;318 ( Pt 2)(Pt 2):575-81. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Myristoyllysophosphatidylcholine
- 13699-45-1
- NOD-like Receptor (NLR)
- Interleukin Related
- Reactive Oxygen Species (ROS)
- Caspase
- TNF Receptor
- Apoptosis
- NLRP3 inflammasome
- RAW 264.7 cells
- IL-1β
- GPI anchor
- VSG
- nagana
- african sleeping sickness
- community-acquired pneumonia
- Trypanosoma brucei
- acute lung injury
- Inhibitor
- inhibitor
- inhibit